Companies: 49,246 Total Market Cap: 132591774254860.43

Gubra A/S

CPH-GUBRA
Healthcare Biotechnology
Rank #9328
Market Cap 995.38 M
Volume 23,203
Price 61.82
Change (%) 1.28%
Country or region Denmark Denmark

Gubra A/S's latest marketcap:

995.38 M

As of 05/20/2025, Gubra A/S's market capitalization has reached $995.38 M. According to our data, Gubra A/S is the 9328th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.

Market Cap 995.38 M
Revenue (ttm) 39.97 M
Net Income (ttm) -5,490,065.66
Shares Out 16.31 M
EPS (ttm) -0.34
Forward PE 13.85
Ex-Dividend Date n/a
Earnings Date 08/21/2025
Market Cap Chart
Data Updated: 05/20/2025

Gubra A/S's yearly market capitalization.

Gubra A/S has seen its market value grow from kr2.04 B to kr6.62 B since 2023, representing a total increase of 224.97% and an annual compound growth rate (CAGR) of 133.14%.
Date Market Cap Change (%)
05/20/2025 kr6.62 B -36.96%
12/30/2024 kr10.18 B 399.74%
12/29/2023 kr2.04 B

Company Profile

About Gubra A/S

Gubra A/S is a biotechnology company specializing in pre-clinical contract research and peptide-based drug discovery, with a focus on metabolic and fibrotic diseases. The company operates across Europe, North America, and internationally.

Business Segments

  • Pre-Clinical Contract Research (CRO): Provides research and development services for pharmaceutical and biotech industries.
  • Discovery & Partnerships: Engages in drug discovery and strategic collaborations.
  • Gubra Green: Focuses on sustainable and innovative biotech solutions.

Services Offered

  • In vivo pharmacology
  • Biomarker assays and bioinformatics
  • Next-gen sequencing
  • Pharmacokinetics
  • 2D and 3D histology with AI pathology

Key Partnerships

  • Boehringer Ingelheim: Collaboration for obesity treatments.
  • Hemab ApS: Partnership to address bleeding disorders.
  • Amylyx Pharmaceuticals, Inc.: Development of a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and rare diseases.

Founded: 2008 | Headquarters: Horsholm, Denmark

Frequently Asked Questions

As of 05/20/2025, Gubra A/S (including the parent company, if applicable) has an estimated market capitalization of $995.38 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.

Gubra A/S global market capitalization ranking is approximately 9328 as of 05/20/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.

Stock Detail

Country or region Denmark
Founded 2008
IPO Date n/a
Employees 260
CEO Henrik Blou
Sector Healthcare
Industry Biotechnology
Address Hørsholm Kongevej 11B
Horsholm, 2970
Denmark
Website https://www.gubra.dk
People Also Watch
VRTX
440.66 1.28%
CSL Limited
156.10 1.28%
REGN
596.54 1.28%
KRX-207940
731.22 1.28%